




The relative strengths and weaknesses of Bridgebio Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bridgebio Pharma Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 9.6% points. The greatest weakness of Bridgebio Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 162% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	548,853	Assets	623,036
Cost of Goods Sold	0	Liabilities	1,867,960
Intangible Assets	28,712	Expenses	589,850
Liabilities, Current	121,428	Revenues	77,648
Liabilities, Non-Current	469,910	Stockholders Equity	-1,244,924
Other Assets	30,902	Net Income	-484,652
Other Compr. Net Income	3,273	Comprehensive Net Income	-483,016
Other Expenses	47,199	BaseVar	1,594,658
Other Liabilities	1,276,622	ECR before LimitedLiability	-257%
Other Net Income	27,550	Economic Capital Ratio	83%
Other Revenues	77,648		
Property and Equipment	14,569		
Research and Development	399,462		
Selling, General and Administrative Expense	143,189		